NCT04736966View on ClinicalTrials.gov

Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Alcoholic Liver Disease
Interventions
DRUG

Guselkumab 30mg

30mg of Guselkumab administered by subcutaneous injection

DRUG

Guselkumab 70mg

70mg of Guselkumab administered by subcutaneous injection

DRUG

Guselkumab 100mg

100mg of Guselkumab administered by subcutaneous injection

Trial Locations (1)

92093

University of California, San Diego, La Jolla

All Listed Sponsors
lead

University of California, San Diego

OTHER

NCT04736966 - Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease | Biotech Hunter | Biotech Hunter